NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading PCRX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on consistent revenue growth and margin maintenance. The current thesis state is intact, supported by strong recent financial results and stable management.
The market currently prices PCRX at a premium compared to its peers, indicating that expectations are somewhat high. There is an expectations gap suggesting that the market anticipates continued strong performance, but this comes with a valuation that is considered expensive.
Fundamentals are likely to remain strong, with management on track to meet revenue and net income targets for 2026. However, there is a moderate risk of missing these targets due to the high-miss-rate nature of the industry.
The thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS, which could influence PCRX's momentum. Guidance cuts or earnings misses from these companies could negatively impact PCRX, while continued strong performance could support its growth.
Overall, PCRX's long-term read remains positive, but it is essential to monitor sector dynamics closely. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance and supports the thesis that the reasons to own the stock remain intact. There are currently no significant threats impacting this outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Growth in EXPAREL sales is important for revenue goals in 2026.
Confirms:EXPAREL net product sales exceed $150 million in Q2 2026.
Disproves:EXPAREL net product sales fall below $140 million in Q2 2026.
Why it matters: Sustaining revenue growth is crucial for achieving the 2026 guidance of $745M to $770M.
Confirms:Q2 total revenue grew more than 5% compared to last year.
Disproves:Q2 total revenue growth falls below 5% year-over-year.
Why it matters: Meeting the revenue guidance of $745M to $770M for 2026 signals strong business momentum.
Confirms:Q2 total revenue was over $185 million. This matches the full-year guidance.
Disproves:Q2 total revenue was below $185 million. This may signal growth problems.
Why it matters: If sector revenue growth drops, it may show bigger problems for Pacira's performance.
Confirms:Sector revenue growth reported below its median of 1% year over year.
Disproves:Sector revenue growth remains above its median of 1% year over year.
Why it matters: Good news could boost investor trust in Pacira's pipeline and future growth.
Confirms one read:Updates show progress in the Phase 2 study of PCRX-201 with good efficacy data.
Confirms the other:Updates reveal setbacks or delays in the Phase 2 study of PCRX-201.
Why it matters: Keeping gross margin in line with guidance shows good cost control and efficiency.
Confirms:Non-GAAP gross margin remains between 77% and 79% in Q2 2026.
Disproves:Non-GAAP gross margin falls below 77% in Q2 2026.
Why it matters: Good results could lead to a new treatment for shoulder osteoarthritis. This would increase sales.
Confirms:Topline results from the Phase 3 study of ZILRETTA are reported as positive.
Disproves:Topline results from the Phase 3 study of ZILRETTA are reported as negative.
Why it matters: Data from this study could impact future revenue and product pipeline strength.
Confirms one read:Positive data from PCRX-201 shows a big drop in knee pain from osteoarthritis.
Confirms the other:Data from PCRX-201 shows no big improvement in knee osteoarthritis pain.
Why it matters: Good results could lead to a new use for ZILRETTA. This would increase revenue.
Confirms:The Phase 3 study of ZILRETTA for shoulder pain shows positive results.
Disproves:The study results are negative or delayed more than expected.
Why it matters: Closing the deal with Zimmer Biomet will strengthen Pacira's balance sheet and focus on core products.
Confirms:The sale of iovera to Zimmer Biomet will finish by Q3 2026.
Disproves:The divestiture is delayed or fails to close due to unmet conditions.
